Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental eye drug aims to slow vision loss in rare genetic disease

NCT ID NCT06852963

First seen Jan 04, 2026 · Last updated May 18, 2026 · Updated 22 times

Summary

This study tests an investigational drug called VP-001, given as an eye injection, for people with a rare genetic form of retinitis pigmentosa caused by PRPF31 mutations. The goal is to see if it is safe and can help slow vision loss. The trial involves 16 adults who have already received VP-001 in earlier studies and will receive two different doses over 26 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RETINAL DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Bascom Palmer Eye Institute - University of Miami

    RECRUITING

    Miami, Florida, 33136, United States

    Contact Email: •••••@•••••

    Contact

  • Baylor College of Medicine

    RECRUITING

    Houston, Texas, 77030, United States

    Contact

    Contact Email: •••••@•••••

  • Casey Eye Institute - OHSU

    RECRUITING

    Portland, Oregon, 97239, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Kellogg Eye Center - University of Michigan

    RECRUITING

    Ann Arbor, Michigan, 48105, United States

    Contact Email: •••••@•••••

    Contact

  • Retina Foundation of the Southwest

    RECRUITING

    Dallas, Texas, 75231, United States

    Contact

    Contact Email: •••••@•••••

  • University of Florida College of Medicine

    RECRUITING

    Jacksonville, Florida, 32209, United States

    Contact Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.